- The Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) have jointly introduced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway.
- According to CMS, this new initiative aims to "expedite Medicare beneficiaries' access to certain FDA-designated Class II and Class III Breakthrough Devices."
- The RAPID pathway specifically targets innovative medical technologies that fall under FDA-designated Class II and Class III Breakthrough Devices, as reported by AMCP.org.
- As stated by the Massachusetts Biotechnology Council, the pathway is designed to streamline the entire process for these advanced medical technologies, potentially enabling Medicare coverage within two months of FDA market authorization.
- This collaboration between CMS and the FDA signifies a concerted effort to accelerate patient access to potentially life-changing medical devices, cutting red tape for innovators.
CMS & FDA Launch RAPID Coverage Pathway
The Centers for Medicare & Medicaid Services (CMS) and the FDA have jointly launched the RAPID coverage pathway, a new initiative designed to significantly expedite Medicare beneficiaries' access to innovative Class II and Class III Breakthrough Devices. This streamlined process aims to secure Medicare coverage for these advanced medical technologies within just two months of FDA market authorization, promising faster access to potentially life-changing treatments.
Reporting Sources
5
Report an issue with this article
Please sign in to report issues with this article.
Live discussion about this article
Comments
Comments are disabled for this article.
